Theophylline reduces histamine release during pollen-induced rhinitis

Robert M. Naclerio, Denise Bartenfelder, David Proud, Alkis G. Togias, Deborah A. Meyers, Anne Kagey-Sobotka, Philip S. Norman, Lawrence M. Lichtenstein

Research output: Contribution to journalArticle

Abstract

In an attempt to understand how theophylline achieves its in vivo therapeutic effect, a double-blind crossover study of the effect of theophylline on the immediate response of the upper airways to challenge with antigen was performed. Ten subjects with allergic rhinitis were challenged with increasing doses of antigen extract, and their responses were assessed by counting the number of sneezes and measuring the level of histamine, N-α-p-tosyl-l-arginine-methyl ester-esterase activity, and kinin in nasal secretions. One-week premedication with theophylline led to serum levels in the therapeutic range (8 to 21 μg/ml). There were significant reductions in both the physiologic response to antigen challenge and the appearance of mediators in secretions after drug administration as compared to placebo. These data suggest that theophylline, at therapeutic blood levels, achieves at least part of its in vivo efficacy by reducing the release of histamine and other mediators from mast cells/basophils.

Original languageEnglish (US)
Pages (from-to)874-876
Number of pages3
JournalThe Journal of Allergy and Clinical Immunology
Volume78
Issue number5 PART 1
DOIs
StatePublished - 1986

Fingerprint

Histamine Release
Theophylline
Rhinitis
Pollen
Antigens
Kinins
Basophils
Premedication
Therapeutic Uses
Esterases
Nose
Double-Blind Method
Mast Cells
Cross-Over Studies
Histamine
Placebos
Therapeutics
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Naclerio, R. M., Bartenfelder, D., Proud, D., Togias, A. G., Meyers, D. A., Kagey-Sobotka, A., ... Lichtenstein, L. M. (1986). Theophylline reduces histamine release during pollen-induced rhinitis. The Journal of Allergy and Clinical Immunology, 78(5 PART 1), 874-876. https://doi.org/10.1016/0091-6749(86)90233-2

Theophylline reduces histamine release during pollen-induced rhinitis. / Naclerio, Robert M.; Bartenfelder, Denise; Proud, David; Togias, Alkis G.; Meyers, Deborah A.; Kagey-Sobotka, Anne; Norman, Philip S.; Lichtenstein, Lawrence M.

In: The Journal of Allergy and Clinical Immunology, Vol. 78, No. 5 PART 1, 1986, p. 874-876.

Research output: Contribution to journalArticle

Naclerio, RM, Bartenfelder, D, Proud, D, Togias, AG, Meyers, DA, Kagey-Sobotka, A, Norman, PS & Lichtenstein, LM 1986, 'Theophylline reduces histamine release during pollen-induced rhinitis', The Journal of Allergy and Clinical Immunology, vol. 78, no. 5 PART 1, pp. 874-876. https://doi.org/10.1016/0091-6749(86)90233-2
Naclerio RM, Bartenfelder D, Proud D, Togias AG, Meyers DA, Kagey-Sobotka A et al. Theophylline reduces histamine release during pollen-induced rhinitis. The Journal of Allergy and Clinical Immunology. 1986;78(5 PART 1):874-876. https://doi.org/10.1016/0091-6749(86)90233-2
Naclerio, Robert M. ; Bartenfelder, Denise ; Proud, David ; Togias, Alkis G. ; Meyers, Deborah A. ; Kagey-Sobotka, Anne ; Norman, Philip S. ; Lichtenstein, Lawrence M. / Theophylline reduces histamine release during pollen-induced rhinitis. In: The Journal of Allergy and Clinical Immunology. 1986 ; Vol. 78, No. 5 PART 1. pp. 874-876.
@article{362faa3268d34c9db882e86980a0c547,
title = "Theophylline reduces histamine release during pollen-induced rhinitis",
abstract = "In an attempt to understand how theophylline achieves its in vivo therapeutic effect, a double-blind crossover study of the effect of theophylline on the immediate response of the upper airways to challenge with antigen was performed. Ten subjects with allergic rhinitis were challenged with increasing doses of antigen extract, and their responses were assessed by counting the number of sneezes and measuring the level of histamine, N-α-p-tosyl-l-arginine-methyl ester-esterase activity, and kinin in nasal secretions. One-week premedication with theophylline led to serum levels in the therapeutic range (8 to 21 μg/ml). There were significant reductions in both the physiologic response to antigen challenge and the appearance of mediators in secretions after drug administration as compared to placebo. These data suggest that theophylline, at therapeutic blood levels, achieves at least part of its in vivo efficacy by reducing the release of histamine and other mediators from mast cells/basophils.",
author = "Naclerio, {Robert M.} and Denise Bartenfelder and David Proud and Togias, {Alkis G.} and Meyers, {Deborah A.} and Anne Kagey-Sobotka and Norman, {Philip S.} and Lichtenstein, {Lawrence M.}",
year = "1986",
doi = "10.1016/0091-6749(86)90233-2",
language = "English (US)",
volume = "78",
pages = "874--876",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "5 PART 1",

}

TY - JOUR

T1 - Theophylline reduces histamine release during pollen-induced rhinitis

AU - Naclerio, Robert M.

AU - Bartenfelder, Denise

AU - Proud, David

AU - Togias, Alkis G.

AU - Meyers, Deborah A.

AU - Kagey-Sobotka, Anne

AU - Norman, Philip S.

AU - Lichtenstein, Lawrence M.

PY - 1986

Y1 - 1986

N2 - In an attempt to understand how theophylline achieves its in vivo therapeutic effect, a double-blind crossover study of the effect of theophylline on the immediate response of the upper airways to challenge with antigen was performed. Ten subjects with allergic rhinitis were challenged with increasing doses of antigen extract, and their responses were assessed by counting the number of sneezes and measuring the level of histamine, N-α-p-tosyl-l-arginine-methyl ester-esterase activity, and kinin in nasal secretions. One-week premedication with theophylline led to serum levels in the therapeutic range (8 to 21 μg/ml). There were significant reductions in both the physiologic response to antigen challenge and the appearance of mediators in secretions after drug administration as compared to placebo. These data suggest that theophylline, at therapeutic blood levels, achieves at least part of its in vivo efficacy by reducing the release of histamine and other mediators from mast cells/basophils.

AB - In an attempt to understand how theophylline achieves its in vivo therapeutic effect, a double-blind crossover study of the effect of theophylline on the immediate response of the upper airways to challenge with antigen was performed. Ten subjects with allergic rhinitis were challenged with increasing doses of antigen extract, and their responses were assessed by counting the number of sneezes and measuring the level of histamine, N-α-p-tosyl-l-arginine-methyl ester-esterase activity, and kinin in nasal secretions. One-week premedication with theophylline led to serum levels in the therapeutic range (8 to 21 μg/ml). There were significant reductions in both the physiologic response to antigen challenge and the appearance of mediators in secretions after drug administration as compared to placebo. These data suggest that theophylline, at therapeutic blood levels, achieves at least part of its in vivo efficacy by reducing the release of histamine and other mediators from mast cells/basophils.

UR - http://www.scopus.com/inward/record.url?scp=0023019456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023019456&partnerID=8YFLogxK

U2 - 10.1016/0091-6749(86)90233-2

DO - 10.1016/0091-6749(86)90233-2

M3 - Article

C2 - 2431021

AN - SCOPUS:0023019456

VL - 78

SP - 874

EP - 876

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 5 PART 1

ER -